Skip to main content

Table 2 Sensitivity and specificity for the respective histopathologic response criterium to predict long term survival

From: Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors

Patients with cN2-3 status

 

Number of patients

Long-term survivors

Sensitivity

Specificity

Sensitivity/(1-specificity)

CMH-test

all patients

157

72

    

pCR

41

28

0.38 (0.27–0.50)

0.84 (0.77–0.92)

2.46 (1.39–4.38)

p = 0.0012

Reg-grade ≥ 2B

72

40

0.56 (0.44–0.67)

0.62 (0.52–0.73)

1.48 (1.05–2.08)

p = 0.025

Reg-grade ≥ 2A

135

66

0.92 (0.85–0.98)

0.19 (0.11–0.27)

1.13 (0.99–1.28)

p = 0.057

pCR-T

46

29

0.40 (0.29–0.51)

0.80 (0.71–0.88)

1.96 (1.18–3.25)

p = 0.008

MNC

85

44

0.61 (0.50–0.72)

0.52 (0.41–0.62)

1.26 (0.95–1.69)

p = 0.11

  1. CMH measures the strength of association between the histopathologic response variable and long term survival which was defined as patient survival ≥ 36 months.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us